Current treatments for Graves’ disease all have drawbacks. Commonly used antithyroid therapies are associated with an increased risk that disease symptoms will return after treatment is stopped. The downside to ablative therapies such as radioiodine therapy or surgery is that many people will eventually develop hypothyroidism, which will require lifelong hormone therapy. Immunotherapies designed to treat the underlying autoimmune process that causes Graves’ disease are under development and are being designed with the goal of restoring immune tolerance to some of the self-proteins targeted by autoimmunity. If these immunotherapies are successful, stopping the underlying autoimmune process could potentially restore thyroid hormones back to normal, healthy levels without inducing hypothyroidism. Some of these therapies are being tested in early-phase clinical trials, with promising results.[1]